Kidney shield? diabetes drug shows promise for teens
NCT ID NCT07591077
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a class of diabetes drugs called SGLT2 inhibitors can slow the progression of kidney disease in adolescents with type 1 diabetes. Researchers measured changes in urine protein levels and blood sugar control over 6 months in 86 participants aged 10-18. The goal was to see if the drug could help control kidney damage, not cure it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEPHROPATHY, DIABETIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ain Shams University
Cairo, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an app and cash rewards tame type 1 diabetes in young adults?
- Smart insulin pump aims to end dangerous nighttime blood sugar swings
- Could diabetes be silently damaging your hearing?
- Hidden liver risk in type 1 diabetes: a new study investigates
- Blood clues: could two proteins reveal how diabetes harms kidneys?
- Can a wearable sensor outsmart diabetic ketoacidosis?